Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Oncology · Cardiotoxicity

Does AML Chemotherapy Cause Long-Term Heart Problems?

At a Glance

Yes, standard "7+3" chemotherapy for acute myeloid leukemia (AML) uses anthracyclines, which can cause long-term heart damage (cardiotoxicity). Because this damage can appear years later, lifelong heart monitoring with regular echocardiograms is an essential part of survivorship.

In this answer

4 sections

01

How Does AML Chemotherapy Affect the Heart?

02

Symptoms to Watch For

03

Your Survivorship Heart Protocol

04

Protecting Your Heart Long-Term

Yes, the standard chemotherapy used to treat acute myeloid leukemia (AML) can cause long-term heart problems. The standard induction treatment—often called the “7+3” regimen—incorporates a class of drugs known as anthracyclines. The specific anthracyclines used for AML are usually daunorubicin or idarubicin [1][2]. While highly effective at clearing leukemia cells, these drugs can cause structural damage to the heart muscle over time, a condition known as cardiotoxicity [3]. Because this damage can appear years after treatment ends, proactive, lifelong heart monitoring is a critical part of your AML survivorship care [4].

How Does AML Chemotherapy Affect the Heart?

Anthracyclines weaken the heart muscle by creating harmful molecules that cause stress and damage to the DNA specifically within your heart cells [5][3].

The risk of heart damage from these drugs is cumulative and dose-dependent [6][7]. This means that the more of the drug you receive over your lifetime, the higher your risk of developing heart complications later [8]. A single, standard course of “7+3” induction chemotherapy typically places you at a moderate risk, but the risk increases significantly if you require additional rounds of chemotherapy for consolidation, if you relapse, or if you receive a bone marrow transplant. It is highly recommended to ask your oncologist for a treatment summary document that lists your exact “cumulative dose” of anthracyclines, so you can share it with future doctors.

It is also important to know that your baseline cardiovascular health matters. Pre-existing conditions—like high blood pressure, diabetes, prior heart disease, or a history of smoking—can compound the risk of developing heart complications after receiving these drugs [9].

Symptoms to Watch For

Late-onset cardiotoxicity often begins as silent, symptom-free damage to the heart muscle before progressing to noticeable heart failure [10][11]. As the heart’s pumping ability weakens, you may begin to experience:

  • Dyspnea: Shortness of breath, especially during physical activity or when lying down flat [12].
  • Extreme fatigue or exercise intolerance [11].
  • Peripheral edema: Swelling in your lower legs, ankles, or feet [10].
  • Palpitations: A feeling that your heart is racing, fluttering, or skipping beats.

If you notice any of these symptoms, even years after your treatment has ended, it is important to notify your healthcare team immediately.

Your Survivorship Heart Protocol

Because heart problems can develop years or even decades after AML treatment, survivors need a structured cardiac monitoring plan [13].

Regular Echocardiograms

The cornerstone of heart monitoring is the echocardiogram (an ultrasound of the heart). This test measures your Left Ventricular Ejection Fraction (LVEF), which is the percentage of blood your heart pumps out with each squeeze [14]. Depending on your cumulative dose of chemotherapy and other personal risk factors, guidelines generally recommend an echocardiogram every 1 to 5 years [15][7].

Modern echocardiograms can also utilize an advanced imaging technique called Global Longitudinal Strain (GLS). GLS is highly recommended because it can detect subtle, subclinical (silent) weakness in the heart muscle before your overall ejection fraction drops [16][17].

Cardiac Biomarkers

In addition to imaging, your doctor may check blood tests for specific cardiac biomarkers, such as NT-proBNP and troponin. These tests help identify early signs of stress or injury to the heart muscle and are valuable tools when paired with regular echocardiograms [18][19].

Protecting Your Heart Long-Term

Detecting heart damage early is crucial because it allows your medical team to intervene before irreversible heart failure occurs [19]. If your monitoring shows early signs of heart weakness, your doctor or a cardio-oncologist (a cardiologist specializing in cancer patients) may prescribe protective medications [20]. Drugs like ACE inhibitors, ARBs, or beta-blockers have been shown to help preserve heart function and prevent the progression of heart failure [21][22].

In addition to monitoring, you can proactively protect your heart by managing modifiable lifestyle factors. Eating a heart-healthy diet, quitting smoking, and strictly managing your blood pressure and cholesterol can significantly reduce your overall cardiovascular risk. Regular aerobic exercise is also encouraged, but it is important to start slowly and consult your doctor before beginning a new exercise routine, especially when your body is still recovering from chemotherapy.

Common questions in this guide

Why does AML chemotherapy cause long-term heart problems?
Standard AML treatments use a class of drugs called anthracyclines, such as daunorubicin or idarubicin. While highly effective at destroying leukemia cells, these drugs can create harmful molecules that stress and damage the DNA within your heart muscle cells over time.
What are the symptoms of chemotherapy-induced heart damage?
Early heart damage is often silent, but as the heart muscle weakens, you may notice shortness of breath, extreme fatigue, swelling in your ankles or feet, and a racing or fluttering heartbeat. You should report any of these symptoms to your doctor immediately, even if it has been years since your treatment.
How often should I get my heart checked after AML treatment?
Most survivorship guidelines recommend getting an echocardiogram every 1 to 5 years after finishing chemotherapy. Your specific monitoring schedule will depend on your total lifetime dose of anthracyclines and whether you have other cardiovascular risk factors like high blood pressure or diabetes.
What is a Global Longitudinal Strain (GLS) test?
Global Longitudinal Strain is an advanced ultrasound technique used during an echocardiogram. It is highly recommended for cancer survivors because it can detect subtle, silent weakness in the heart muscle before your overall pumping function drops to abnormal levels.
Can heart damage from chemotherapy be treated or prevented?
Yes, if regular monitoring detects early signs of heart weakness, a cardiologist or cardio-oncologist can prescribe protective medications like ACE inhibitors or beta-blockers. You can also protect your heart by managing your blood pressure, eating a healthy diet, and quitting smoking.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my total cumulative dose of anthracyclines (daunorubicin or idarubicin), and does that put me in a higher risk category for heart issues?
  2. 2.Based on my treatment history and personal risk factors, how often should I be getting an echocardiogram to check my ejection fraction?
  3. 3.Does the echocardiography facility you refer to use Global Longitudinal Strain (GLS) imaging to detect early signs of heart muscle weakness?
  4. 4.Should we be checking blood biomarkers like NT-proBNP and troponin alongside my regular echocardiograms?
  5. 5.Given my health history, would it be beneficial for me to establish care with a specialized cardio-oncologist now?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can You Be Diagnosed with AML with Less Than 20% Blasts?Does the Treatment Center Matter for AML Survival?How Do FLT3 and NPM1 Mutations Affect AML?How Do Doctors Assess Fitness for AML Chemotherapy?How is Venetoclax Given for Acute Myeloid Leukemia?How Long Does Chemo Brain Last After AML Treatment?What Are the ELN Risk Categories in AML?What Are AML Induction & Consolidation Therapies?What Are AML Skin and Gum Symptoms? | Inciteful MedWhat Conditions Mimic Acute Myeloid Leukemia?What Does MRD Negative Mean in Acute Myeloid Leukemia?What is cGVHD After an AML Stem Cell Transplant?What Is a Day 14 Bone Marrow Biopsy in AML Treatment?

References

References (22)
  1. 1

    Can we forecast induction failure in acute myeloid leukemia?

    Thol F

    Haematologica 2018; (103(3)):375-377 doi:10.3324/haematol.2018.187575.

    PMID: 29491126
  2. 2

    Beyond the first glance: anthracyclines in AML.

    Fernandez HF

    Blood 2015; (125(25)):3828-9 doi:10.1182/blood-2015-04-639419.

    PMID: 26089377
  3. 3

    Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury.

    Avagimyan A, Pogosova N, Kakturskiy L, et al.

    Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2024; (73()):107683 doi:10.1016/j.carpath.2024.107683.

    PMID: 39111556
  4. 4

    Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment.

    Saleh Y, Abdelkarim O, Herzallah K, Abela GS

    Heart failure reviews 2021; (26(5)):1159-1173 doi:10.1007/s10741-020-09968-2.

    PMID: 32410142
  5. 5

    Regulated cell death pathways in doxorubicin-induced cardiotoxicity.

    Christidi E, Brunham LR

    Cell death & disease 2021; (12(4)):339 doi:10.1038/s41419-021-03614-x.

    PMID: 33795647
  6. 6

    Cardiovascular disease in survivors of childhood cancer.

    Bansal N, Amdani SM, Hutchins KK, Lipshultz SE

    Current opinion in pediatrics 2018; (30(5)):628-638 doi:10.1097/MOP.0000000000000675.

    PMID: 30124579
  7. 7

    Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

    de Baat EC, van Dalen EC, Mulder RL, et al.

    The Lancet. Child & adolescent health 2022; (6(12)):885-894 doi:10.1016/S2352-4642(22)00239-5.

    PMID: 36174614
  8. 8

    Dexrazoxane makes doxorubicin-induced heart failure a rare event in sarcoma patients receiving high cumulative doses.

    Zheng H, Zhan H

    Cardio-oncology (London, England) 2025; (11(1)):29 doi:10.1186/s40959-025-00323-8.

    PMID: 40108682
  9. 9

    Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML.

    Sorror ML, Agarwal S, Othus M, et al.

    Cancer medicine 2020; (9(18)):6515-6523 doi:10.1002/cam4.3311.

    PMID: 32706528
  10. 10

    Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines.

    Liu X, Ge S, Zhang A

    Children (Basel, Switzerland) 2024; (11(7)) doi:10.3390/children11070884.

    PMID: 39062333
  11. 11

    Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients.

    Cuomo A, Rodolico A, Galdieri A, et al.

    Cardiac failure review 2019; (5(2)):112-118 doi:10.15420/cfr.2018.32.2.

    PMID: 31179022
  12. 12

    Anthracyclines-Induced Cardiac Dysfunction: What Every Clinician Should Know.

    Ferrera A, Fiorentini V, Reale S, et al.

    Reviews in cardiovascular medicine 2023; (24(5)):148 doi:10.31083/j.rcm2405148.

    PMID: 39076747
  13. 13

    Case Report: Diffuse Large B Cell Lymphoma After Cardiac Transplantation due to Anthracycline-Induced Dilated Cardiomyopathy in Pediatric Acute Lymphoblastic Leukemia.

    Xin N, Chunyan C, You Z, et al.

    Frontiers in pharmacology 2022; (13()):769751 doi:10.3389/fphar.2022.769751.

    PMID: 35517799
  14. 14

    Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology.

    Kostakou PM, Kouris NT, Kostopoulos VS, et al.

    Heart failure reviews 2019; (24(1)):91-100 doi:10.1007/s10741-018-9731-y.

    PMID: 30073443
  15. 15

    Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients: A Systematic Review.

    Liesse K, Harris J, Chan M, et al.

    Journal of pediatric hematology/oncology 2018; (40(6)):417-425 doi:10.1097/MPH.0000000000001118.

    PMID: 29432315
  16. 16

    Correlation of Speckle-Tracking Echocardiography with Traditional Biomarkers in Predicting Cardiotoxicity among Pediatric Hemato-Oncology Patients: A Comprehensive Evaluation of Anthracycline Dosages and Treatment Protocols.

    Ardelean AM, Olariu IC, Isac R, et al.

    Children (Basel, Switzerland) 2023; (10(9)) doi:10.3390/children10091479.

    PMID: 37761440
  17. 17

    Anthracycline-Induced Cardiomyopathy in Adults.

    Tan TC, Neilan TG, Francis S, et al.

    Comprehensive Physiology 2015; (5(3)):1517-40 doi:10.1002/cphy.c140059.

    PMID: 26140726
  18. 18

    Biomarkers and Strain Echocardiography for the Detection of Subclinical Cardiotoxicity in Breast Cancer Patients Receiving Anthracyclines.

    Bhagat AA, Kalogeropoulos AP, Baer L, et al.

    Journal of personalized medicine 2023; (13(12)) doi:10.3390/jpm13121710.

    PMID: 38138937
  19. 19

    Early Predictive Value of NT-proBNP Combined With Echocardiography in Anthracyclines Induced Cardiotoxicity.

    Dong Y, Wu Q, Hu C

    Frontiers in surgery 2022; (9()):898172 doi:10.3389/fsurg.2022.898172.

    PMID: 35846969
  20. 20

    Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis.

    Liu R, Fan C, Liu X, et al.

    Cardio-oncology (London, England) 2025; (11(1)):65 doi:10.1186/s40959-025-00332-7.

    PMID: 40624671
  21. 21

    Renin-angiotensin System Antagonists and Beta-blockers in Prevention of Anthracycline Cardiotoxicity: a Systematic Review and Meta-analysis.

    Avila MS, Siqueira SRR, Waldeck L, et al.

    Arquivos brasileiros de cardiologia 2023; (120(5)):e20220298 doi:10.36660/abc.20220298.

    PMID: 37255127
  22. 22

    The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.

    Blanter JB, Frishman WH

    Cardiology in review 2019; (27(5)):256-259 doi:10.1097/CRD.0000000000000252.

    PMID: 31008768

This page is for informational purposes only and does not replace professional medical advice. Always consult your oncologist or cardiologist regarding your specific heart risks and survivorship monitoring plan.

Get notified when new evidence is published on Acute myeloid leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.